Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

29

Revenue 2017

Soliris

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Soliris was produced by Alexion.

NICE broadens access to Alexion's rare disease drug Strensiq

NICE broadens access to Alexion's rare disease drug Strensiq s reliance on its primary product Soliris (eculizumab), its $2.8bn treatment for atypical haemolytic uraemic syndrome (aHUS).

A new decade of disruption: meeting the biosimilar challgenge

A new decade of disruption: meeting the biosimilar challgenge In some cases, more: topping $400, 000 per year, Soliris (eculizumab) is one of the costliest drugs available globally.

Alexion Pharmaceutiacal names interim CEO and CFO

Alexion Pharmaceutiacal names interim CEO and CFO They succeed David Hallal and Vikas Sinha, who both stepped down from their roles amid an investigation into the company's sales practices for rare blood disease therapy Soliris (eculizumab).

Bio investors react as Clinton tweet pledges pricing crackdown

Bio investors react as Clinton tweet pledges pricing crackdown Alexion's 3.6% fall stems from the fact that it sells the world's most expensive drug - Soliris (eculizumab) for two ultra-rare diseases - which costs more than 500, 000

Humira remains top pharma product, but Sovaldi closes in

Humira remains top pharma product, but Sovaldi closes in The rare disease drug Soliris (eculizumab) has also made an appearance in the top 50 list - but only just - taking forty-eight place with sales of $2.2bn in 2014, registering ... But with rarity comes a high cost, with Soliris' price tag around $500, 000

[ Previous 5 results ] 1 2 3 4 5 6 7 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...

Infographics